PUMA
Istituto di Fisiologia Clinica     
Andreassi M. G., Botto N., Maffei S. Trombofilia genetica e terapia ormonale: indicazioni per lo screening genetico. In: Menopause Surveillance, vol. 6 - giugno pp. 1 - 11. 2005.
 
 
Abstract
(English)
Venous thromboembolism is a well-known complication of oral contraception and hormonal replacement therapy. Inherited thrombophilia is viewed to be an important determinant in modulating the effects of estrogens on thrombotic risk. An increasing number of commercial kits for thrombophilic mutations (factor V Leiden, G20210A prothrombin and MTHFR C677T genes) are becoming available commercially, and screening for inherited thrombotic risk is among the most requested genetic test in molecular diagnostic laboratories. However, the question of routine genetic screening for thrombophilia before prescribing hormones is still a matter of debate.The purpose of this article is to discuss the usefulness and the practical applications of thrombotic genetic testing in order to define which women should be tested for improving both the safety and efficacy of individualized estrogen therapy.
Subject Trombofilia ereditaria


Icona documento 1) Download Document PDF


Icona documento Open access Icona documento Restricted Icona documento Private

 


Per ulteriori informazioni, contattare: Librarian http://puma.isti.cnr.it

Valid HTML 4.0 Transitional